BiotechTube
Home/Kotobuki Pharmaceutical/Tatsunori Iwai
TI

Tatsunori Iwai

Director in charge of Research Promotion

Kotobuki Pharmaceutical

Therapeutic Areas

OncologyGastroenterologyNeurologyMetabolic DiseasePain

Kotobuki Pharmaceutical Pipeline

DrugIndicationPhase
Gilteritinib (XOSPATA®)FLT3-mutated Relapsed/Refractory Acute Myeloid LeukemiaApproved
Tramadol HCl OD TabletsCancer & Chronic PainApproved
Zonisamide OD TabletsEpilepsyApproved
MARZULENE-S / AZULOXAGastritis & Peptic UlcerApproved
SUJANU® Combination TabletsType 2 DiabetesApproved

Leadership Team at Kotobuki Pharmaceutical

HT
Hiroshi Tomiyama
President & CEO
KS
Kazuhiro Satou
Director in charge of General Affairs
OY
Osami Yamaura
Director in charge of Sales
AN
Atsushi Noda
Director in charge of Manufacturing
WU
Wataru Uchida, Ph.D.
Outside Director
View full Kotobuki Pharmaceutical profile